Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea
- 1 June 2020
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 30 (6), 764-771
- https://doi.org/10.1136/ijgc-2020-001200
Abstract
Objective The aim of this study was to compare the clinical outcomes of chemoradiotherapy with or without bevacizumab in patients with newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) stage IVB cervical cancer. Methods 41 patients with stage IVB cervical cancer who underwent chemoradiotherapy between August 2015 and December 2017 were retrospectively analyzed. This study included 11 patients who received bevacizumab before or after radiotherapy (group A) and 30 patients who received conventional chemoradiotherapy without bevacizumab (group B). We excluded the following patients: those with dual primary cancers; those whose pathologic diagnosis was neither squamous cell carcinoma nor adenocarcinoma; those who did not undergo radiotherapy; or those from whom follow-up data could not be collected. We analyzed the treatment responses, toxicities, progression-free survival, and overall survival rates. Results A total of 41 patients were included in the analysis. The median follow-up was 19 months (range 3-108). The response rates at 3 months after treatment were 90.9% in group A and 83.3% in group B (p=0.54). After completing all treatments, the complete response rates were 81.8% in group A and 47% in group B (p=0.04). Grade >= 3 gastrointestinal toxicities, including bleeding, fistula, perforation, and obstruction, were more frequent in group A (54.5%) than in group B (6.7%) (p=0.003). The 12 month progression-free survival and overall survival rates were similar in both arms (12 month progression-free survival: 45.5% vs 46.7%, respectively, p=0.22; 12 month overall survival: 81.8% vs 72.9%, respectively, p=0.57). Patients with node-only metastasis had better 12 month progression-free survival in group B than in group A (59.1% vs 42.9%, respectively, p=0.04). However, the responses to both treatments did not differ in patients with organ metastasis. Conclusions Bevacizumab for stage IVB cervical cancer is associated with higher complete response rates. However, patients treated with bevacizumab experienced more bowel toxicities. Bevacizumab did not improve progression-free survival among patients with node-only metastasis.Funding Information
- National Cancer Center (1810271-3)
This publication has 20 references indexed in Scilit:
- Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)The Lancet, 2017
- Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income CountriesJournal of Global Oncology, 2017
- Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus StatementJournal of Gynecologic Oncology, 2017
- Improved Survival with Bevacizumab in Advanced Cervical CancerThe New England Journal of Medicine, 2014
- Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic MetastasisCancer Research and Treatment, 2013
- Curative Chemoradiotherapy in Patients With Stage IVB Cervical Cancer Presenting With Paraortic and Left Supraclavicular Lymph Node MetastasesInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Outcomes and toxicities for the treatment of stage IVB cervical cancerArchiv für Gynäkologie, 2011
- Revised FIGO staging for carcinoma of the cervixInternational Journal of Gynecology & Obstetrics, 2009
- Revised FIGO staging for carcinoma of the vulva, cervix, and endometriumInternational Journal of Gynecology & Obstetrics, 2009
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000